Pfizer To Pay $2.3B In Bextra Off-Label Marketing Suit

Law360, New York (January 27, 2009, 12:00 AM EST) -- Pfizer Inc. has agreed to pay $2.3 billion to settle allegations that it improperly marketed the now-defunct anti-inflammatory drug Bextra, the pharmaceutical giant disclosed Monday.

The settlement, which still needs court approval, was reached with the office of U.S. Attorney Michael Sullivan of the District of Massachusetts.

According to a statement put out by Pfizer, the deal will resolve “previously disclosed investigations regarding allegations of past off-label promotional practices concerning Bextra, as well as other open investigations.”

The company added that its net income for the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.